Degenerative Discopathy Involving L4-L5 Clinical Trial
Official title:
"Ex Vivo" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease
The present prospective, randomized study, compares the spinal fusion obtained after
instrumentation and the use of a biologic product (patient's mesenchymal cells obtained from
his/her own bone marrow which will be fixed in human bone tissue form a donor), with the
current procedure that consists in instrumented spinal fusion and the use of each patient's
bone obtained from his/her iliac crest.
The working hypothesis proposes that the tissue engineering is a valid and useful technique
to achieve bone regeneration, avoiding the need for obtaining patient's iliac crest and its
associated morbidity.
Prospective, open-label, randomized, parallel, single-dose phase I-II clinical trial in which
62 patients affected with L4-L5 degenerative spondylolisthesis grade I-II according to
Meyerding and/or with L4-L5 degenerative discopathy needing spinal fusion will enter the
trial with the primary objective of assessing the feasibility and safety of "ex-vivo"
expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion.
Secondary objectives are to assess the efficacy of the implantation by imaging (computerized
helicoidal tomography and X-ray) and clinical questionnaires (pain by visual analogue scale,
quality of life by SF-36 and Oswestry Disability Index).
Patients will be randomized to one of the two treatment arms (instrumented spinal fusion and
the tissue engineering product composed by "ex-vivo" expanded autologous mesenchymal stem
cells fixed in allogenic bone tissue in spinal fusion or the standard treatment of
instrumented spinal fusion and patient's bone iliac crest). Thereafter, patients will be
followed for 12 months.
Imaging assessment will be done by an independent blinded radiologist.
;